This review attempts to show that, considering the mutational landscape of Smo and its role in cancer, identification of Smo mutations through tumour genetic screening can enhance diagnosis and guide the choice of medication to ensure the best therapeutic outcomes for cancer patients. The gene discussed is SMO; the disease is cancer.